Ultrasound-guided prostate tissue sampling, often combined with MRI fusion, to confirm or rule out prostate cancer with precision.
Transrectal ultrasound (TRUS)-guided prostate biopsy is a procedure that samples small cores of tissue from the prostate gland, using a thin ultrasound probe placed in the rectum to guide the biopsy needle in real time. Because the prostate sits directly in front of the rectum, this approach gives excellent, close-up imaging of the gland, allowing tissue to be sampled from precise, pre-planned locations, or from a specific area of concern.
The tissue samples obtained are examined by a pathologist under a microscope to determine whether prostate cancer is present, and if so, how aggressive it appears (its Gleason score or grade group) — information that's central to deciding on the right treatment approach, or confirming that no treatment is needed at all.
Particularly when the pattern of change over time raises concern.
A firm or irregular area felt by the examining doctor.
A standardised score grading how likely an area is to represent significant cancer.
For men with low-risk prostate cancer being carefully followed rather than treated.
Antibiotics and, where needed, bowel preparation beforehand.
Previously acquired MRI images are aligned with the live ultrasound view.
A fine needle collects multiple tissue cores, plus any MRI-targeted areas.
Most men go home the same day.
A prostate biopsy isn't the first step in prostate cancer evaluation — it follows an initial suspicion raised by other tests, and the decision to proceed is made individually by the referring urologist based on the overall clinical picture:
An elevated or rising PSA blood test, particularly when the pattern of change over time (PSA velocity) or the PSA relative to prostate size (PSA density) raises concern.
An abnormal finding on digital rectal examination, such as a firm or irregular area felt by the examining doctor.
A suspicious lesion identified on prostate MRI, scored using a standardised system (PI-RADS) that grades how likely a given area is to represent clinically significant cancer.
Monitoring during active surveillance, for men already diagnosed with low-risk prostate cancer who are being carefully followed rather than treated immediately, to confirm the cancer hasn't become more aggressive over time.
Traditional TRUS-guided biopsy samples the prostate in a standardised, systematic pattern across the gland, since cancer usually can't be reliably seen on ultrasound alone. This approach works well overall but can sometimes miss cancer in certain locations, or occasionally lead to a needless biopsy in a man who doesn't actually have clinically significant disease. A multiparametric MRI performed before biopsy can identify specific suspicious areas within the prostate, graded by how concerning they look.
Where a suspicious area is identified on MRI, this can be used to directly guide the biopsy — an approach called MRI-TRUS fusion biopsy, in which the MRI images are electronically overlaid onto the live ultrasound picture during the procedure, letting the operator target the exact suspicious area seen on MRI, in addition to the standard systematic sampling pattern. This combined approach has been shown to improve detection of clinically significant cancer while helping avoid unnecessary detection of very low-risk disease that may not need treatment. Where MRI shows no suspicious area at all, a standard systematic TRUS biopsy alone may still be recommended, depending on the overall clinical picture.
Preparation: a short course of antibiotics is typically prescribed around the time of the procedure to reduce infection risk, and bowel preparation, such as an enema, may be advised beforehand depending on local protocol.
Positioning and anaesthesia: the procedure is usually performed with the patient lying on their side, and local anaesthetic is injected around the prostate to numb the area before biopsy — this local block has made the procedure considerably more comfortable than older techniques.
Imaging and sampling: the ultrasound probe is placed in the rectum, and, if MRI fusion is being used, the previously acquired MRI images are aligned with the live ultrasound view. A fine needle is then passed to collect multiple tissue cores — commonly 12 or more from a standard systematic pattern, plus additional targeted cores from any suspicious area identified on MRI.
Recovery: the procedure itself typically takes 15 to 30 minutes, and most men go home the same day, generally advised to take it easy for the rest of that day.
Mild discomfort, some blood in the urine, semen, or stool, is common for a period after the procedure — blood in the semen in particular can persist, on and off, for several weeks, which is expected and not a cause for concern. More significant bleeding, fever, or difficulty passing urine should be reported promptly to the treating team, since these can be early signs of infection or other complications needing attention. Results from the pathology laboratory are typically available within about a week, at which point the referring urologist will discuss the findings and, if relevant, the recommended next steps.
The most clinically important risk following prostate biopsy is infection, since the needle path can carry bacteria from the rectum into the prostate and bloodstream — this is specifically why antibiotics are given around the time of the procedure, and why a transperineal approach (through the skin between the scrotum and rectum, rather than through the rectal wall) is increasingly used in some centres, since it further reduces this particular infection risk. Other risks include bleeding, temporary difficulty passing urine, and, uncommonly, a more significant infection requiring hospital treatment. Overall, the procedure is safe and very widely performed, but these risks are discussed individually with each patient beforehand as part of informed consent.
Getting the most diagnostic value from a prostate biopsy — accurately targeting any suspicious MRI finding while adequately sampling the rest of the gland, with the lowest possible risk of infection or bleeding — depends on close coordination between the referring urologist, who manages the overall diagnostic pathway and interprets the results, and the team performing the image-guided biopsy itself. This is why prostate biopsy planning, particularly where MRI fusion is being used, works best as a shared process between urology and interventional radiology rather than a standalone step.
The procedure is done under local anaesthesia, which has made it considerably more comfortable than older techniques. Most men describe pressure or brief discomfort rather than significant pain, and it's generally well tolerated.
A prior MRI can identify specific suspicious areas within the prostate, which can then be directly targeted during the biopsy (MRI-TRUS fusion biopsy) alongside standard sampling — this combined approach improves detection of significant cancer while helping avoid unnecessary biopsy of very low-risk findings.
Yes — mild blood in the urine, semen, or stool is common and expected for a period afterward, and blood in the semen in particular can persist on and off for several weeks. Significant bleeding, fever, or difficulty urinating should be reported to your care team promptly.
Pathology results are typically available within about a week, at which point your referring urologist will go through the findings and discuss any recommended next steps with you.
A transrectal biopsy passes the needle through the rectal wall, while a transperineal biopsy passes it through the skin between the scrotum and rectum instead — an approach increasingly used in some centres because it further reduces infection risk.
Book a consultation with Dr. Giragani, or send your reports for a specialist second opinion.